Iovance reports record Q3 2026 revenue of about $122 million
FROM THE WIRE · GLOBENEWSWIRE.COM
Total Revenue Increased ~80% and U.S. Amtagvi Revenue Increased ~77% Year-over-Year, and Gross Margin Increased to ~60% 24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous Metastatic Non-Small-Cell Lung Cancer (mNSCLC) 59.1% ORR in Biomarker-Selected mNSCLC…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRecord revenue and strongly rising gross margin for a commercial biotech company.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Total revenue increased about 80% year over year.
- 02U.S. Amtagvi revenue increased about 77% year over year.
- 03Gross margin rose to about 60%.
- 04The POSITILITY trial and the SARATOGA registrational trial are underway.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets